Three-Year Exclusivity Questioned By Sen. Edwards, GPHA’s Jaeger

Sen. John Edwards (D-N.C.) may be interested in re-examining the three-year market exclusivity provision under Hatch/Waxman as discussion on generic drug reform moves forward on Capitol Hill